MARTINA VIS: Open Payments
NPI 1659922805 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,246 in 52 payments from 15 companies in 2025. Trend: 2023 $916 · 2024 $1,553 · 2025 $1,246
Food & beverage: $1,195Education: $51
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $250 |
| ABBVIE INC. | 9 | $198 |
| Madrigal Pharmaceuticals | 5 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Regeneron Healthcare Solutions, Inc. | 4 | $117 |
| Novo Nordisk Inc | 2 | $104 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Ardelyx, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, ENTYVIO, Wegovy, RINVOQ, INJECTAFER, IBSRELA.
Industry payments across GA — which companies pay providers there.
